MaxCyte

MaxCyte Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of MaxCyte (MXCT) as of Oct 5, 2026 is 360.54. In the previous year, Cash Conversion Cycle (CCC) was 432.68 — a change of -16.67% (lower).

Cash Conversion Cycle

360.54

YoY

-16.67%

Last updated:

Cash Conversion Cycle (CCC) of MaxCyte is 2026 360.54 . Cash Conversion Cycle (CCC) of MaxCyte was 2025 432.68 . It decreases by -16.67% lower compared to the previous year.

The MaxCyte Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-265.73 USD
Jan 1, 2019
289.51 USD
Jan 1, 2020
524.41 USD
Jan 1, 2021
412.98 USD
Jan 1, 2022
705.62 USD
Jan 1, 2023
935.18 USD
Jan 1, 2024
432.68 USD
Jan 1, 2025
360.54 USD
The MaxCyte Cash Conversion Cycle history
YEARCash Conversion CycleYoY
360.54-16.67%
432.68-53.73%
935.18+32.53%
705.62+70.86%
412.98-21.25%
524.41+81.14%
289.51-208.95%
-265.73-60.10%
-666.02+50.62%
-442.19+24.44%
-355.35+281.42%
-93.16—
Access this data via the Eulerpool API

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Cash Conversion Cycle (CCC) of MaxCyte is 360.54 in 2026.

Cash Conversion Cycle (CCC) of MaxCyte changed from 432.68 to 360.54, representing a -16.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) MaxCyte since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s MaxCyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — MaxCyte

All Key Metrics — MaxCyte